# Contact Wolverine Research — Editorial Inquiries on BPC-157 TB-500

> Contact Wolverine Research with editorial corrections or source suggestions for our BPC-157 TB-500 coverage. We do not provide medical advice, prescriptions, or any product.

Corrections, source suggestions, and editorial questions about our BPC-157 TB-500 coverage.

## Editorial inquiries only

Wolverine Research is an editorial terminal covering the BPC-157 TB-500 literature, and this desk handles editorial matters only: corrections, citation suggestions, and questions about how we read a study. If you believe a figure or citation on this site is wrong, tell us which page and which `[N]` marker, and we will check it against the source.

We do not provide medical or legal advice, we do not answer dosing questions, and we do not supply, sell, or facilitate access to either peptide or the blend. Questions about treatment belong with an appropriately licensed prescriber, not with an editorial publisher.

## Send a message

Use the form below to reach the editorial desk. Include the page URL and, where relevant, the citation number so we can trace a claim to its source quickly. We read every message but cannot offer individualized health guidance, and we will not respond to requests to obtain, price, or supply the compound.

For the regulatory and access picture, the [Wolverine legal status](/legal-status) page already lays out the present-tense FDA 503A and WADA record; for the human dataset, see the [BPC-157 TB-500 clinical evidence](/clinical-evidence) page before writing in.

---

A two-position evidence board for the BPC-157 TB-500 blend — each constituent finding posted up where the studies confirm it and down where the combination row stays empty, the FDA 503A and WADA status read off first, and nothing here listed, priced, or for sale.